100 related articles for article (PubMed ID: 20671370)
1. Heparin cofactor II attenuates vascular remodeling in humans and mice.
Aihara K
Circ J; 2010 Aug; 74(8):1518-23. PubMed ID: 20671370
[TBL] [Abstract][Full Text] [Related]
2. Heparin cofactor II as a novel vascular protective factor against atherosclerosis.
Aihara K; Azuma H; Akaike M; Sata M; Matsumoto T
J Atheroscler Thromb; 2009 Oct; 16(5):523-31. PubMed ID: 19729870
[TBL] [Abstract][Full Text] [Related]
3. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.
Aihara K; Azuma H; Akaike M; Ikeda Y; Sata M; Takamori N; Yagi S; Iwase T; Sumitomo Y; Kawano H; Yamada T; Fukuda T; Matsumoto T; Sekine K; Sato T; Nakamichi Y; Yamamoto Y; Yoshimura K; Watanabe T; Nakamura T; Oomizu A; Tsukada M; Hayashi H; Sudo T; Kato S; Matsumoto T
J Clin Invest; 2007 Jun; 117(6):1514-26. PubMed ID: 17549254
[TBL] [Abstract][Full Text] [Related]
4. Vascular dermatan sulfate and heparin cofactor II.
Tollefsen DM
Prog Mol Biol Transl Sci; 2010; 93():351-72. PubMed ID: 20807652
[TBL] [Abstract][Full Text] [Related]
5. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention.
Takamori N; Azuma H; Kato M; Hashizume S; Aihara K; Akaike M; Tamura K; Matsumoto T
Circulation; 2004 Feb; 109(4):481-6. PubMed ID: 14744972
[TBL] [Abstract][Full Text] [Related]
6. Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis.
Rau JC; Mitchell JW; Fortenberry YM; Church FC
Semin Thromb Hemost; 2011 Jun; 37(4):339-48. PubMed ID: 21805439
[TBL] [Abstract][Full Text] [Related]
7. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals.
Aihara K; Azuma H; Takamori N; Kanagawa Y; Akaike M; Fujimura M; Yoshida T; Hashizume S; Kato M; Yamaguchi H; Kato S; Ikeda Y; Arase T; Kondo A; Matsumoto T
Circulation; 2004 Jun; 109(22):2761-5. PubMed ID: 15148272
[TBL] [Abstract][Full Text] [Related]
8. Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors.
Aihara K; Azuma H; Akaike M; Kurobe H; Takamori N; Ikeda Y; Sumitomo Y; Yoshida S; Yagi S; Iwase T; Ishikawa K; Sata M; Kitagawa T; Matsumoto T
J Atheroscler Thromb; 2009 Apr; 16(2):127-34. PubMed ID: 19403987
[TBL] [Abstract][Full Text] [Related]
9. Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice.
Sumitomo-Ueda Y; Aihara K; Ise T; Yoshida S; Ikeda Y; Uemoto R; Yagi S; Iwase T; Ishikawa K; Hirata Y; Akaike M; Sata M; Kato S; Matsumoto T
Hypertension; 2010 Sep; 56(3):430-6. PubMed ID: 20660821
[TBL] [Abstract][Full Text] [Related]
10. Heparin cofactor II modulates the response to vascular injury.
Tollefsen DM
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
[TBL] [Abstract][Full Text] [Related]
11. Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.
Rau JC; Deans C; Hoffman MR; Thomas DB; Malcom GT; Zieske AW; Strong JP; Koch GG; Church FC
Exp Mol Pathol; 2009 Dec; 87(3):178-83. PubMed ID: 19747479
[TBL] [Abstract][Full Text] [Related]
12. Heparin cofactor II inhibits arterial thrombosis after endothelial injury.
He L; Vicente CP; Westrick RJ; Eitzman DT; Tollefsen DM
J Clin Invest; 2002 Jan; 109(2):213-9. PubMed ID: 11805133
[TBL] [Abstract][Full Text] [Related]
13. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.
Vicente CP; He L; Tollefsen DM
Blood; 2007 Dec; 110(13):4261-7. PubMed ID: 17878401
[TBL] [Abstract][Full Text] [Related]
14. Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events.
Huang PH; Leu HB; Chen JW; Wu TC; Lu TM; Yu-An Ding P; Lin SJ
Int J Cardiol; 2007 Jan; 114(2):152-8. PubMed ID: 16650906
[TBL] [Abstract][Full Text] [Related]
15. Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors.
Ise T; Aihara K; Sumitomo-Ueda Y; Yoshida S; Ikeda Y; Yagi S; Iwase T; Yamada H; Akaike M; Sata M; Matsumoto T
Hypertens Res; 2011 Feb; 34(2):225-31. PubMed ID: 21107326
[TBL] [Abstract][Full Text] [Related]
16. [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role].
Rossi EB; Duboscq CL; Kordich LC
Medicina (B Aires); 1999; 59(1):95-104. PubMed ID: 10349131
[TBL] [Abstract][Full Text] [Related]
17. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting.
Schillinger M; Exner M; Sabeti S; Mlekusch W; Amighi J; Handler S; Quehenberger P; Kalifeh N; Wagner O; Minar E
Thromb Haemost; 2004 Nov; 92(5):1108-13. PubMed ID: 15543340
[TBL] [Abstract][Full Text] [Related]
18. Heparin cofactor II significance for the inhibition of thrombin at the injured vessel wall.
Pasche B; Swedenborg J; Frebelius S; Olsson P
Thromb Res; 1991 Jun; 62(5):409-19. PubMed ID: 1896960
[TBL] [Abstract][Full Text] [Related]
19. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.
Huang SS; Huang PH; Chen YH; Sung SH; Chiang KH; Chen JW; Lin SJ
Coron Artery Dis; 2008 Dec; 19(8):597-602. PubMed ID: 18971786
[TBL] [Abstract][Full Text] [Related]
20. Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.
He L; Giri TK; Vicente CP; Tollefsen DM
Blood; 2008 Apr; 111(8):4118-25. PubMed ID: 18281504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
